ALFA Finder| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 12.0 | 16.0 | 25.6 |
| Other income | 5.7 | 0.0 | 4.2 |
| Total income | 17.7 | 16.0 | 29.8 |
| Profit before exceptional items & tax | -147.0 | -16.6 | -5.5 |
| Profit before tax | -147.0 | -16.6 | -5.5 |
| Net profit | -147.1 | -16.6 | -5.6 |
| Operating margin | -830.5% | -103.8% | -18.5% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Revenue, year on year | -53.10% |
|---|
BSE results filing, NSE: VIVIMEDLAB. Figures extracted from the filing.
Vivimed Labs Ltd: key numbers
- Share price
- ₹5.40
- Market cap
- ₹44.77 Cr
- Revenue (annual)
- ₹69.99 Cr
- Net profit (annual)
- ₹-176.5 Cr
- P/E (TTM)
- -0.2×Sector 43.8×
- Promoter holding
- 7.57%-0.20% QoQ
- FII holding
- 1.64%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Vivimed Labs Ltd
All →Vivimed Labs Insolvency Petition
Vivimed Labs Limited, currently under CIRP, has scheduled the 8th meeting of the Committee of Creditors for September 29, 2026, via audio-visual means.
Vivimed Labs Other Announcement
Vivimed Labs is seeking a three-month extension from the Registrar of Companies to convene its Annual General Meeting for the financial year 2025-26.
Vivimed Labs Other Announcement
Vivimed Labs Limited, currently under corporate insolvency resolution, has announced its 7th Committee of Creditors meeting scheduled for September 10, 2026, to be held virtually.
Vivimed Labs Insolvency Petition
Vivimed Labs, undergoing CIRP, has scheduled the 6th meeting of the Committee of Creditors for August 18, 2026, as per regulatory requirements.
Vivimed Labs Board Meeting Date
Vivimed Labs scheduled a board meeting on July 17, 2026. The board will consider audited financial results for the period ending March 31, 2026.
Vivimed Labs Results Correction
Vivimed Labs replied to NSE's clarification request regarding financial results. The company submitted a revised Statement of Impact of audit qualifications.